Decades after the 1918 flu pandemic, epidemiologists discovered that survivors were up to three times as likely to develop Parkinson’s disease. This wasn’t a…
Women were historically excluded from medical research. The move was originally intended to keep them safe — but in a way, it did the…
When the COVID-19 pandemic hit in 2019, researchers raised concerns it would increase the risk of neurodegenerative diseases like Alzheimer’s and Parkinson’s. A recent…
There’s a hereditary typo in Doug Whitney’s genetic code: a variant that all but guarantees its carriers will contract Alzheimer’s disease within their lifetime….
Eisai and Biogen’s Alzheimer’s drug Leqembi (generic name lecanemab) was the first fully-FDA approved disease-modifying treatment for early-stage Alzheimer’s disease in United States history,…
Can a seemingly harmless virus in the gut wreak havoc on the brain decades after the initial infection? And could catching and treating an…
Roughly a quarter of all Americans over the age of 40 in the U.S. take statin drugs — which lower levels of cholesterol —…
In 1907, a Belgian chemist named Leo Baekelend developed a revolutionary new material that would soon become a hallmark of the modern era: fully…
In the brains of people with Alzheimer’s diseases, problematic proteins called beta-amyloid build up and clump together in plaques, harming and eventually killing off…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
A Trump executive order has banned DEI initiatives across the federal government. Scientists say the move could undermine trial diversity and derail the quest…
When Eisai announced in a press release this week that they’d secured FDA approval for an Alzheimer’s drug dosage change, it seemed like a…
In 2023, U.S. Surgeon General Dr. Vivek Murthy sounded the alarm about the social isolation and loneliness epidemic. A recent poll found that three…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Two days after President Donald Trump took office, sweeping bans — mostly temporary — went into effect across the U.S. National Institutes of Health…